LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

Inclusion Criteria:

1. Men or women, ≥18 to 85 years of age

2. NYHA Class II or III or ambulatory NYHA Class IV symptoms

3. A diagnosis of World Health Organization (WHO) Group 2 PH-HFpEF with qualifyinghemodynamics verified by right heart catheterization (RHC)

4. A qualifying baseline RHC

5. A qualifying echocardiogram

6. A qualifying 6-MWD

7. A 48-hour ambulatory cardiac rhythm monitor during the Screening Period

8. Requirements related to child bearing potential, contraception, and egg/spermdonation)

Exclusion Criteria:

1. A diagnosis of PH WHO Groups 1, 3, 4, or 5

2. Echocardiographic evidence for hypertrophic cardiomyopathy, restrictivecardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrativecardiomyopathy

3. Structural heart repair or replacement of the aortic valve or mitral valve (surgicalor percutaneous) OR, planned valve intervention OR, the presence of significantvalve disease

4. A diagnosis of pre-existing lung disease

5. History of severe allergic or anaphylactic reaction or hypersensitivity to theexcipients in the investigational product

6. Major surgery within 60 days

7. Prior heart, lung, or heart-lung transplants or life expectancy of <12 months

8. History of clinically significant other diseases that may limit or complicateparticipation in the study